Androgen deprivation therapy (ADT) + SRT + REZVILUTAMIDE for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Sep 2023: Trial started, NCT06305832
  2. 12 Mar 2024: Trial registered, NCT06305832

The trials

NCT06305832: Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

State
Under way
Phase
Phase 2
People
102 planned
Started
7 Sep 2023
Primary completion
Mar 2028
Arms
Rezvilutamide +ADT+ SRT
Results
None posted
  1. 7 Sep 2023: Trial started
  2. 12 Mar 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.